Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Pfizer's stock underperformed its healthcare peers since PFE topped out in late July 2024. Click here to find out why I ...

We recently published a list of 10 Best Innovative Stocks that Pay Dividends. In this article, we are going to take a look at ...

The results could pave the way for Pfizer's drug ponsegromab to become the first-ever approved treatment specifically for ...

Pharmaceutical giant Pfizer ( PFE 2.73%) stands out in this context. The company currently offers a mouthwatering 5.7% ...

Jefferies analyst Akash Tewari maintained a Buy rating on Pfizer (PFE – Research Report) today and set a price target of $35.00. The ...

Pfizer Inc (NYSE: PFE) presented positive trial data for experimental drug designed for patients suffering from cancer ...

Shares of Pfizer Inc. PFE dropped 0.81% to $29.42 Friday, on what proved to be an all-around mixed trading session for the ...

The company's best days as a top pandemic vaccine supplier might be over, but it still has enough potential to be compelling.

Pfizer is trying to increase doctor awareness of and testing for a rare lung cancer mutation to help boost use of its drug ...

A drug that could reduce the risk of death in cancer patients is showing good promise during its second phase of clinical ...

Financial giants have made a conspicuous bearish move on Pfizer. Our analysis of options history for Pfizer PFE revealed 8 ...